Predictors of pathological upstaging in clinical stage T1 renal cell carcinoma include male gender, age, and irregular margins
Could your kidney tumor look smaller than it really is inside?
This meta-analysis and systematic review evaluated 24,957 patients with clinical stage T1 renal cell carcinoma to identify predictors of pat…
A kidney tumor that looks small on a scan might actually be more advanced than doctors think, raising the risk of it returning after surgery…
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
PI3K-AKT-mTOR pathway activation linked to renal cell carcinoma progression in review
Review explores potential kidney cancer treatment target and challenges
A review article summarizes literature on the PI3K-AKT-mTOR signaling pathway in renal cell carcinoma (RCC).
Kidney cancer tumors often overactivate a cell pathway that drives growth and spreading, prompting doctors to explore blocking it with new d…
Research across Urologic Neoplasms
Related studies from across the Urologic Neoplasms family.
Fianlimab plus cemiplimab showed objective response rates of 20% to 33% in advanced solid tumors during a Phase 1 study.
Early trial shows new cancer drug combo helps some patients with advanced disease
This Phase 1, first-in-human dose-expansion study evaluated fianlimab 1600 mg plus cemiplimab 350 mg in patients with advanced non-small cel…
A new drug combination helped some patients with advanced lung, kidney, head and neck, or skin cancer shrink their tumors in early testing.
ADRB1 and ADRB2 antihypertensive target perturbations associated with increased clear cell renal cell carcinoma risk
Genetic markers linked to blood pressure drugs raise kidney cancer risk
This meta-analysis of Mendelian randomization and colocalization analyses found that genetic perturbations equivalent to antihypertensive dr…
Genetic data suggests certain blood pressure targets may increase clear cell renal cell carcinoma risk, a finding that warrants attention fo…
Angiogenic ccRCC tumors show higher pancreatic metastasis rate in phase II trial
Pancreatic Metastases Predict Better Sunitinib Response in Kidney Cancer
This phase II RCT of 305 treatment-naive ccRCC patients found that angiogenic tumors had a higher rate of pancreatic metastases (21% vs. 6.9…
Kidney tumors with certain genetic patterns are more likely to spread to the pancreas. Patients with these pancreatic metastases respond bet…
Meta-analysis shows active surveillance and ablative therapy for small renal masses have comparable cancer-specific survival
Active surveillance vs ablation for small kidney tumors: what works?
This systematic review and meta-analysis evaluates active surveillance (AS) versus ablative therapy (AT) for patients with small renal masse…
For small kidney tumors, ablation may boost survival, but cancer-specific death risk is similarly low with either approach.
Prospective study shows active surveillance yields high survival for small renal masses under 2 cm
Small kidney tumors may not need surgery right away
This prospective multi-institutional study evaluated active surveillance in patients aged over 50 years with asymptomatic, unilateral small …
Many small kidney tumors stay harmless for years, meaning patients might avoid surgery and its risks without putting their health in danger.
Low ipilimumab trough concentration linked to worse progression-free survival in metastatic clear cell renal cell carcinoma
Low Drug Levels Mean Worse Outcomes
This randomized phase 2 trial evaluated nivolumab and ipilimumab trough plasma concentrations in 110 patients with metastatic clear cell ren…
Low levels of a common kidney cancer drug are linked to worse survival outcomes when used with another powerful medicine.
CFP10 immunohistochemistry shows high sensitivity for renal tuberculosis in surgical specimens
New Test Finds Hidden TB in Kidney Tissue
A retrospective cohort study of 86 patients with surgically resected renal tissue found CFP10 immunohistochemical staining had 91.8% sensiti…
A new kidney test spots hidden tuberculosis by finding a specific protein that standard methods often miss, helping doctors catch the infect…
Meta-analysis shows ERAS care improves recovery and reduces complications in laparoscopic nephrectomy for renal cancer
ERAS Care Helps Kidney Cancer Patients Heal Faster
This meta-analysis evaluated enhanced recovery after surgery (ERAS) versus traditional care in 2,361 patients undergoing laparoscopic radica…
Kidney cancer patients recovering from surgery heal faster with a special plan, eating and walking sooner while spending less time in the ho…
Questions about Renal Cell Carcinoma
What does the Hong Kong consensus statement recommend for managing metastatic renal cell carcinoma?
The Hong Kong consensus recommends immunotherapy-based combinations for first-line metastatic renal cell carcinoma, active surveillance for select patients, and specific strategies for non-clear cell or sarcomatoid subtypes.
Full answer →What factors predict pathological upstaging in clinical stage T1 renal cell carcinoma?
Male gender, older age, higher BMI, larger tumor size (cT1b), irregular margins, tumor necrosis on imaging, and higher RENAL score predict pathological upstaging in cT1 RCC.
Full answer →Can adjuvant pembrolizumab benefit selected high-risk patients with renal cell carcinoma?
Yes, adjuvant pembrolizumab benefits selected high-risk RCC patients after surgery, improving disease-free and overall survival based on the KEYNOTE-564 trial.
Full answer →